These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 34098294

  • 1. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM, Noor-E-Alam M, Mohite P, Islam MS, Modestino AS, Peckham AM, Young LD, Young GJ.
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [Abstract] [Full Text] [Related]

  • 2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY.
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.
    Al Faysal J, Noor-E-Alam M, Young GJ, Lo-Ciganic WH, Goodin AJ, Huang JL, Wilson DL, Park TW, Hasan MM.
    Comput Biol Med; 2024 Jul; 177():108493. PubMed ID: 38833799
    [Abstract] [Full Text] [Related]

  • 7. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J, Saunders J.
    BMC Psychiatry; 2022 Jul 30; 22(1):516. PubMed ID: 35908052
    [Abstract] [Full Text] [Related]

  • 8. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP.
    Drug Alcohol Depend; 2019 Jul 01; 200():34-39. PubMed ID: 31082666
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H, Williams AR, Olfson M, Crystal S.
    J Subst Abuse Treat; 2018 Dec 01; 95():9-17. PubMed ID: 30352671
    [Abstract] [Full Text] [Related]

  • 12. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.
    Addiction; 2014 Jan 01; 109(1):79-87. PubMed ID: 23961726
    [Abstract] [Full Text] [Related]

  • 13. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
    Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA.
    Drug Alcohol Depend; 2021 Aug 01; 225():108764. PubMed ID: 34051547
    [Abstract] [Full Text] [Related]

  • 14. Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People.
    Lillie KM, Shaw J, Jansen KJ, Garrison MM.
    J Addict Med; 2021 Aug 01; 15(4):297-302. PubMed ID: 33074852
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B.
    Addiction; 2022 Jul 01; 117(7):1972-1981. PubMed ID: 35257434
    [Abstract] [Full Text] [Related]

  • 17. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ, Mark TL, Zarkin GA, Weber E.
    Addiction; 2022 Jan 01; 117(1):141-150. PubMed ID: 34033177
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L, Iversen J, Wand H, Maher L.
    Addiction; 2021 Mar 01; 116(3):525-535. PubMed ID: 32557931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.